Last reviewed 2026-05-19 · How we verify

celecoxib test formulation C1

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

celecoxib test formulation C1 is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently in Phase 1 development.

Celecoxib is a small molecule cyclooxygenase-2 inhibitor that belongs to the drug class of INHIBITOR. A pilot open-label crossover bioavailability study (NCT00813241) was conducted to evaluate the pharmacokinetics of celecoxib in healthy volunteers, comparing the reference formulation with test formulations A1 and B2.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	celecoxib test formulation C1
Sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

celecoxib test formulation C1 CI brief — competitive landscape report
celecoxib test formulation C1 updates RSS · CI watch RSS
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI

Frequently asked questions about celecoxib test formulation C1

What is celecoxib test formulation C1?

celecoxib test formulation C1 is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Who makes celecoxib test formulation C1?

celecoxib test formulation C1 is developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (see full Pfizer's Upjohn has merged with Mylan to form Viatris Inc. pipeline at /company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc).

What development phase is celecoxib test formulation C1 in?

celecoxib test formulation C1 is in Phase 1.

Manufacturer: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing